Andrea G. Gordon, MT(ASCP)SH

• Vice President of Academic Affairs
• River Valley Community College
• Claremont, New Hampshire

Hypothalamic neurons connect directly to the posterior pituitary to regulate production of oxytocin and vasopressin acne home treatments 20 gm betnovate order with amex. Alternatively acne laser removal order betnovate paypal, the hypothalamus communicates with the anterior pituitary through secretion of peptide factors into the pituitary portal blood; through this mechanism the hypothalamus controls the secretion of growth hormone delex acne buy 20 gm betnovate fast delivery, thyroid stimulating hormone acne zinc 20 gm betnovate mastercard, follicle stimulating hormone acne and pregnancy 20 gm betnovate buy otc, luteinizing hormone, thyroid stimulating hormone and prolactin. Typically, pharmacology associated with treatment of hypothalamic and pituitary disorders focuses on replacing a hormone that is lacking or blocking a hormone that is overproduced. Prolactin is the only anterior pituitary hormone under tonic inhibition by a hypothalamic hormone. Gonadotropins bind with high affinity to membrane glycoprotein receptors in the testes and ovaries encoded by homologous genes and characterized by seven transmembrane-spanning domains. In addition to regulating estrogen production, gonadotropins have multiple effects on ovarian follicles. The Sertoli cell is necessary for maintenance of seminiferous tubule function and germ cell development. The prohormone is stored in neurosecretory granules that travel down the supraoptico-hypophyseal tract to the posterior pituitary. V1 receptors mediate vasoconstriction, while V2 receptors mediate antidiuretic effects. Mature spermatogenesis was achieved in 50% of patients, and men with unfused epiphyses experienced linear bone growth. Idiopathic or surgically induced hypogonadotropic hypogonadism is treated with testosterone to promote masculinization and to preserve bone mineral density. Orchiectomy, an effective and relatively safe surgical procedure that significantly lowers testosterone levels (90%), is less desirable in men with cancer because of the emotional impact. Such therapy can also lead to tumor shrinkage in 30% of patients treated for acromegaly. Women with hyperprolactinemia commonly present with oligomenorrhea, amenorrhea, or infertility. Men with hyperprolactinemia commonly present with decreased libido, erectile dysfunction, and other signs of low testosterone, including osteoporosis. Decreases in prolactin concentration occur within 2­3 weeks of initiating therapy, but significant abatement of the clinical signs and symptoms of the intracranial tumor may be noted within days. A significant reduction of tumor size may be seen within 6 weeks of initiating therapy. With reduction of the serum prolactin concentration to normal, galactorrhea is abolished and gonadal function restored. Renal excretion represents its primary route of elimination, and thus renal insufficiency decreases the overall clearance rate. In a recent study, the use of gonadotropins for ovulation induction in women with polycystic ovary syndrome was successful in approximately 70% of patients, with 40% achieving pregnancy. Multiple-gestation births occur in approximately 10% to 15% of patients receiving gonadotropins. The gonadotropins, both urinary and recombinant, can be used to induce spermatogenesis in the treatment of male-factor infertility. Bromocriptine, a long-acting agonist, reaches peak plasma levels in 1 hour, has a half-life of about 6 hours, and is heavily bound to serum albumin (>90%). Cabergoline is another long-acting dopamine agonist with a high affinity for D2 receptors. After a single oral dose, mean peak plasma levels are observed within 2 to 3 hours, with a significant fraction undergoing first-pass metabolism. The elimination half-life is 63 to 69 hours, allowing twice-weekly administration. These effects can be minimized if therapy is begun with low doses and administered with food and at bedtime, with gradual increased frequency as appropriate. A few patients experience headache, fatigue, abdominal cramping, nasal congestion, drowsiness, or diarrhea. Ovarian enlargement and extravascular accumulation of fluid resulting in ascites, pleural and pericardial effusions, renal failure, and hypovolemic shock are potentially life-threatening. Ovarian enlargement can be classified as mild, moderate, or severe; the incidence of massive ovarian enlargement of greater than 12 cm is rare (<2%). All are metabolized in liver and kidney and may be inactivated initially by cleavage of the C-terminal glycinamide. Other signs and symptoms may relate directly to specific pressor and antidiuretic effects. Vasoconstriction may be mild, leading to skin blanching or abdominal cramping, or may be life-threatening, leading to angina or myocardial infarction. All preparations should be used with caution in patients with coronary artery disease; desmopressin has lower pressor effects and may be a drug of choice. Signs and symptoms of hyponatremia include drowsiness, listlessness, weakness, headaches, seizures, and coma. Side effects and clinical problems associated with the use of the hypothalamic and pituitary hormones and their analogues are summarized in the Clinical Problems Box. Development of recombinant analogues, largely replacing naturally occurring purified hormones, is continuing and should be beneficial in clinical therapy. Alterations of any of these regulatory factors can put patients at risk during various healthcare encounters. For example, alteration of hypothalamic function can increase sensitivity to Epi, resulting in increased risk of arrhythmias, increased sweating, and tremors. Use of Epi in dental practice, if systemically absorbed, could induce an arrhythmia. Tremors and increased sweating could be mistaken for some other issue by nurses or physician assistants or produce an altered response to physical therapy interventions. Therefore awareness of the endocrine status of a patient, and any therapeutic intervention, can provide the healthcare practitioner important information relevant to care being administered. A young man with central diabetes insipidus was given desmopressin rather than arginine vasopressin because desmopressin: A. A 28-year-old woman wanted to get pregnant, but she was infertile as a consequence of central amenorrhea. A 27-year-old man with acromegaly, who is not a surgical candidate, has been experiencing metabolic issues. To prevent further development, her endocrinologist prescribed which of the following Cortisol, the primary endogenous glucocorticoid in humans, is involved in the regulation of intermediary metabolism, the stress response, some aspects of central nervous system function, and the regulation of immunity. The main therapeutic uses of the glucocorticoids are (1) replacement therapy for patients exhibiting inadequate endogenous cortisol production; (2) antiinflammatory or immunosuppressant agents; and (3) adjuvants in the treatment of myeloproliferative diseases and other malignant conditions. The major therapeutic use of the synthetic mineralocorticoids is replacement for patients with primary adrenal insufficiency or isolated aldosterone deficiency. Similarly, drugs that antagonize corticosteroid receptors may be warranted when corticosteroids are overproduced. A summary of the use of the glucocorticoids, mineralocorticoids, and other agents for the treatment of adrenocorticosteroid disorders is presented in the Therapeutic Overview Box. These drugs are widely used for their antiinflammatory or other abilities, but the adverse effects can be debilitating. For some people, the drugs are lifesaving, and so the adverse effects must be tolerated, if not controllable. Additionally, excessive cortisol (Cushing syndrome) must also be treated, or those same adverse effects will be present in those patients. The antiinflammatory actions of these compounds include: · Decreased production of prostaglandins, cytokines, and interleukins · Decreased proliferation and migration of lymphocytes and macrophages In addition, the glucocorticoids increase circulating neutrophils, inhibit macrophage antigen processing, suppress T-helper cell function, and induce eosinopenia and lymphopenia. Even with increases in neutrophils, glucocorticoids decrease their accumulation at inflammatory sites. This action, along with the suppression of the phagocytic, bactericidal, and antigen-processing activity of these cells, compromises the immune system. Glucocorticoids can have profound direct and indirect effects on the central nervous system. Glucocorticoids also regulate growth and development, particularly in fetal tissues, where it induces surfactant synthesis in the lungs before birth. As a result, cortisol can lessen the severity of respiratory distress syndrome due to insufficient surfactant secretion in preterm infants. Mineralocorticoids Aldosterone, the major mineralocorticoid produced by the adrenal cortex, acts primarily at the distal portion of the convoluted renal tubule to promote the reabsorption of Na+ and the excretion of K+ to maintain homeostasis. Corticosteroid Receptors All natural and synthetic corticosteroids act by binding to specific receptors that are members of the nuclear receptor superfamily, leading to alterations in gene transcription (Chapter 2). Steroidogenesis Inhibitors and Corticosteroid Receptor Antagonists Drugs that inhibit steroid biosynthesis include mitotane, metyrapone, and ketoconazole. Glucocorticoids decrease glucose uptake in many tissues and stimulate liver glucose production, possibly to protect the brain and heart. They also disrupt lipid metabolism and facilitate the lipolytic effects of other agents to increase gluconeogenesis, again as a possible protection of the heart and brain. If adequate glucocorticoid levels are achieved but more mineralocorticoid effects are required, fludrocortisone is supplemented. Plasma cortisol concentrations should be measured in patients with suspected acute adrenal insufficiency, and, if low, patients should be treated immediately with intravenous hydrocortisone. Intermediateacting glucocorticoids are also used for treatment of bronchial asthma and chronic obstructive pulmonary disease. Alternate day­therapy glucocorticoid administration, developed to reduce adverse effects, involves administration of double the normal daily dose of an intermediate-acting glucocorticoid, such as prednisone, every other day. However, alternate-day therapy can become problematic, with some patients finding this approach intolerable because of fluctuations of hormone levels and inconvenience. Dexamethasone and betamethasone have minimal to no mineralocorticoid activity and maximal antiinflammatory activity. They should not be used long term because of their bone demineralization properties and growth suppression in children. Mitotane is also the drug of choice for patients with inoperable adrenocortical carcinoma. For patients with Cushing syndrome who are glucose intolerant or who have type 2 diabetes, mifepristone is used. Mifepristone is the first oral drug approved by the United States Food and Drug Administration to control hyperglycemia in Cushing syndrome. Spironolactone is effective for lowering blood pressure in patients with primary hyperaldosteronism (Chapter 39). Different structural modifications of some topical glucocorticoids can alter lipophilicity and solubility, changing systemic absorption characteristics that may result in systemic effects following excessive and prolonged local application. Fludrocortisone (9-fluorohydrocortisone) is the mineralocorticoid drug of choice for the treatment of primary adrenocortical insufficiency, aldosterone insufficiency, salt-losing congenital adrenal hyperplasia, and idiopathic orthostatic hypotension. The benefits include enhanced reabsorption of Na+ from renal tubules with excretion of K+ and H+ to promote fluid and electrolyte balance. Prednisone, prednisolone, and methylprednisolone have intermediate plasma half-lives, whereas betamethasone and dexamethasone are long-acting analogues. The liver and kidney are the major sites of glucocorticoid inactivation, which typically involves reduction of the double bond at position 4/5, reduction of the keto group at position 3, hydroxylation at position 6, and side-chain cleavage. Approximately 30% of inactivated cortisol is metabolized to tetrahydrocortisol-glucuronide and tetrahydrodeoxycortisol-glucuronide and excreted in the urine. Inducers of hepatic drug metabolism, such as rifampin, may accelerate the hepatic biotransformation of the glucocorticoids and necessitate an increase in dose. The half-life of aldosterone is very short (a few minutes), and without ongoing secretion from the adrenals, its rapid clearance from plasma effectively limits its biological effects. Steroidogenesis Inhibitors and Corticosteroid Receptor Antagonists Mitotane is 40% absorbed following oral administration and is distributed throughout the body with fat as the primary site. It is metabolized to a water-soluble compound that is excreted in the urine and bile and has a median half-life of 53 days. Itisreducedto metyrapol, which is an active alcohol metabolite, and both parent and metyrapol are excreted as glucuronides. Excessive exposure to glucocorticoids leads to Cushing syndrome, characterized by hypertension, truncal obesity, diabetes, hirsutism, acne, moonfacies,proximalmuscleweakness,widepurplestriaovertheskin, and behavioral abnormalities. The syndrome results most commonly from the exogenous administration of glucocorticoids, but there are also endogenous causes. Acute adrenal insufficiency is the most serious problem that may occur, while the possible return or "flare-up" of the underlying disease is the most frequent problem. Although patient response to withdrawal is variable, established protocols for corticosteroid withdrawal should be followed to minimize issues. Other characteristics of withdrawal syndrome may include fever, myalgia, arthralgia, malaise, and, in rare circumstances, even pseudotumor cerebri. In most children, linear growth rate is impaired with long-term glucocorticoid therapy. Intheabsence of a surgical cure, an important inhibitor is spironolactone, which is also used clinically as a diuretic and an antihypertensive agent. Further, altered immune responses predispose the patient to increased susceptibility to infection or reactivation of latent infections, a very dangerous complication of long-term glucocorticoid treatment. A major side effect of glucocorticoids, especially when given for prolonged periods, is their detrimental action on bone leading to osteoporosis. Glucocorticoids cause osteoporosis by disrupting the regulation of Ca++ metabolism at several levels: (1) by decreasing the intestinal absorption and renal reabsorption of Ca++; (2) by exerting a direct catabolic action on bone by inhibiting osteoblastic activity; and (3) by blocking the protective effect of calcitonin (Chapter 55). Mitotanecontainsaboxed warning for drug discontinuation following shock or severe trauma because its primary action is adrenal suppression. The adverse effects associated with the use of ketoconazole are presented in Chapter 62, those for mifepristone in Chapter 51, and those for spironolactone in Chapter 39.

Instead acne 30s quality betnovate 20 gm, because their metabolism produces bicarbonate acne 2017 buy betnovate 20 gm mastercard, their excretion enables alkali excretion without altering urine pH acne forum buy betnovate 20 gm with visa. Citrate may also inhibit calcium oxalate nucleation by colloidal stabilization of early-stage calcium oxalate complexes skin care tips in urdu best buy for betnovate. Citrate has two roles in acid­base homeostasis: (1) as a urinary buffer contributing to titratable acid excretion acne and menopause purchase betnovate with mastercard, and (2) as a substrate in the tricarboxylic acid cycle. The two primary molecular forms of citrate, citrate-3 and citrate-2, exist in equilibrium with each other: Citrate-3 + H + Citrate-2 the pKa of this buffer reaction is ~6. Other molecular forms, citrate-1 and citrate0, because of the pKa of the appropriate buffer reactions, are at such sufficiently low concentrations that they appear to not be transported to a significant extent. Because glomerular filtrate has a pH essentially identical to systemic arterial pH, essentially all filtered citrate is in the form of citrate-3. The second mechanism through which citrate contributes to acid­base homeostasis relates to its function as a metabolic substrate for the tricarboxylic acid cycle. Citrate excretion thereby enables base excretion without altering urine pH, which may be beneficial for minimization of pH-dependent calcium nucleation and calcium-containing stone growth. The carbonic anhydrase inhibitor, acetazolamide, and a high dietary intake of either NaCl or protein decrease citrate excretion. The proximal tubule reabsorbs a variable proportion, typically 65%­90%, of filtered citrate, and reabsorption parallels the filtered load. Citrate transported into proximal tubule cells, whether across apical or basolateral plasma membranes, is fully metabolized, enabling citrate to serve as a significant component of renal oxidative metabolism. Because many conditions stimulate luminal acidification, this provides a mechanism to increase filtered citrate reabsorption without altering the number or activity of citrate transporters. One is the calcineurin inhibitor target protein, cyclophilin,33 which likely mediates the effects of calcineurin inhibitors to increase citrate reabsorption. Because organic anions can be metabolized to bicarbonate, organic anion excretion is functionally equivalent to alkali excretion and thereby can contribute to acid­base regulation. The extent of change in these organic anions with acid­base disturbances is not clear. Some studies show acid or alkali loading does not alter urinary organic anion excretion,235 whereas other studies show alkali loading increases and acid loading decreases organic anion excretion177 Quantitatively, there are important species-dependent differences in the magnitude of organic anion excretion. This reaction occurs essentially instantaneously and has a pKa under biologically relevant conditions of ~9. Glutamine synthetase is expressed in the proximal tubule and in intercalated cells, and its expression decreases in response to metabolic acidosis88,226 and, in the proximal tubule, with hypokalemia. Ammonia metabolism involves integrated function of multiple portions of the kidney. Only a minimal amount of urinary ammonia derives from glomerular filtration, making urinary ammonia excretion unique among the major compounds present in the urine. Instead, the kidney produces ammonia, which is then selectively transported either into the urine or the renal vein, where it is transported to the systemic circulation. Numbers in blue represent the proportion of total excreted ammonia at each location. Proximal tubule-specific glutamine synthetase deletion blunts the decrease in ammonia excretion in response to dietary protein restriction. Ammonia production rates in different renal components measured in microdissected components from rats on control diets and after inducing metabolic acidosis. Metabolic acidosis increases total renal ammoniagenesis, but only through increased production in proximal tubule segments (S1, S2, and S3). Rates (pmol/mm) were calculated from measured ammonia production rates and mean length per segment as described in Good and Burg. Acute metabolic acidosis induces a rapid, ~twofold increase in plasma glutamine levels; this results primarily from increased skeletal muscle and hepatic glutamine release. Under basal conditions, luminal glutamine reabsorbed in the proximal tubule not used for ammoniagenesis can be transported across the basolateral plasma membrane. This process involves a specific transporter-mediated mechanism, is trans-stimulated and cis-inhibited by alanine, and is stimulated by metabolic acidosis. Multiple pathways for enzymatic ammonia production originating from glutamine metabolism are present in the proximal tubule. This results in counter current amplification of medullary interstitial ammonia concentration. Studies in the rat show ammonia secretion in the micropuncturable distal tubule could account for ~10%­15% of ammonia excretion. There is increased protein expression, and this appears to be transcriptionally mediated. It also mediates an important role in the renal response to metabolic acidosis,58 coincident with increased renal gluconeogenesis. These studies have demonstrated that some, but not all, aquaporin-family members can transport ammonia. Intercalated cell-specific Rhbg deletion, while not altering ammonia excretion, induces adaptive changes in other enzymes involved in ammonia metabolism that appear to compensate for its absence, indicating a role for Rhbg under basal conditions. In general, type A intercalated cells express higher levels of Rhcg than do principal cells. Rhcg has an important role in renal ammonia excretion in a wide variety of conditions, including basal acid­base homeostasis, metabolic acidosis, hypokalemia, and several other conditions. There are changes in total protein expression in a variety of conditions, as detailed earlier. This mechanism may help to coordinate ammonia and proton secretion beyond physicochemical driving forces. Multiple studies have addressed the molecular form of ammonia that Rhcg transports. Several studies using Rhbg and/or Rhcg deletion show that Rhbg and Rhcg expression are not necessary for urine acidification. They are expressed throughout the kidney, but levels are highest in the outer and inner medulla and metabolic acidosis increases medullary interstitial sulfatide content. Disruption of renal sulfatide synthesis, by a genetic approach along the entire renal tubule, led to lower urinary pH accompanied by lower ammonium excretion. Candidate molecular sensors have included acid-/alkali-sensing receptors, tyrosine kinases, and bicarbonatestimulated adenylyl cyclase. It is found in the kidney in the basolateral plasma membrane of type B cell and non-A, non-B intercalated cells,28 and is activated by alkaline pH. Diurnal variation in net acid excretion is altered in uric acid stone formers and may contribute to the pathogenesis of nephrolithiasis in this condition. This activation involves a receptor tyrosine kinase, possibly a member of the ErbB family,486 and may involve ErbB1/2 heterodimerization and activation of receptor tyrosine phosphatase-. Proximal tubulespecific glutamine synthetase deletion alters basal and acidosisstimulated ammonia metabolism. Localization of the ammonium transporter proteins, Rh B glycoprotein and rh C glycoprotein, in the mouse kidney. The interaction of pendrin and the epithelial sodium channel in blood pressure regulation. Axial heterogeneity of sodiumbicarbonate cotransporter expression in the rabbit proximal tubule. Regulation of renal phosphate transport by acute and chronic metabolic acidosis in the rat. Remodeling the cellular profile of collecting ducts by chronic carbonic anhydrase inhibition. Adaptation of inner medullary collecting duct vacuolar H-adenosine triphosphatase to chronic acid or alkali loads in the rat. Insulin receptorrelated receptor expression in non-A intercalated cells in the kidney. Functional cooperation of epithelial heteromeric amino acid transporters expressed in Madin-Darby canine kidney cells. Intercalated cellspecific Rh B glycoprotein deletion diminishes renal ammonia excretion response to hypokalemia. Stimulation of renal Na+ dicarboxylate cotransporter 1 by Na+/H+ exchanger regulating factor 2, serum and glucocorticoid inducible kinase isoforms, and protein kinase B. The effect of lithium and related metal ions on the urinary excretion of 2-oxoglutarate and citrate in the rat. The role of the renal ammonia transporter Rhcg in metabolic responses to dietary protein. Haploinsufficiency of the ammonia transporter rhcg predisposes to chronic acidosis: Rhcg is critical for apical and basolateral ammonia transport in the mouse collecting duct. Transport of organic anions across the basolateral membrane of proximal tubule cells. The calcium sensing receptor modulates fluid reabsorption and acid secretion in the proximal tubule. Bicarbonate transport along the loop of Henle: molecular mechanisms and regulation. Axial heterogeneity of vasopressin-receptor subtypes along the human and mouse collecting duct. Control mechanisms of bicarbonate transport across the rat proximal convoluted tubule. Lithium treatment induces a marked proliferation of primarily principal cells in rat kidney inner medullary collecting duct. Inhibition of glutamine synthetase in the mouse kidney: a novel mechanism of adaptation to metabolic acidosis. The distribution of glutaminase isoenzymes in the various structures of the nephron in normal, acidotic, and alkalotic rat kidney. Proteomic analysis of the adaptive response of rat renal proximal tubules to metabolic acidosis. Renal compensation to chronic hypoxic hypercapnia: downregulation of pendrin and adaptation of the proximal tubule. The calcineurin homologous protein-1 increases na(+)/H(+) -exchanger 3 trafficking via ezrin phosphorylation. Ammonium transport in the kidney: new physiological concepts and their clinical implications. Effect of respiratory acidosis and respiratory alkalosis on renal transport enzymes. Immunolocalization of aquaporin-8 in rat kidney, gastrointestinal tract, testis, and airways. Reabsorption and secretion of alpha-ketoglutarate along the rat nephron: a micropuncture study. Ammonium and bicarbonate transport in isolated perfused rodent long-loop thin descending limbs. Mechanisms through which ammonia regulates cortical collecting duct net proton secretion. Deoxycorticosteronestimulated bicarbonate secretion in rabbit cortical collecting ducts: effects of luminal chloride removal and in vivo acid loading. Immunolocalization of the secretory isoform of Na-K-Cl cotransporter in rat renal intercalated cells. Inhibition of bicarbonate absorption by peptide hormones and cyclic adenosine monophosphate in rat medullary thick ascending limb. Effects of osmolality on bicarbonate absorption by medullary thick ascending limb of the rat. Functional roles of apical membrane Na+/ H+ exchange in rat medullary thick ascending limb. Effect of hypokalemia on renal expression of the ammonia transporter family members, Rh B glycoprotein and Rh C glycoprotein, in the rat kidney. Expression of the ammonia transporter family members, Rh B glycoprotein and Rh C glycoprotein, in the developing rat kidney. Response of the collecting duct to disturbances of acid-base and potassium balance. Localization of the calcium-regulated citrate transport process in proximal tubule cells. Structural organization and associated splicing defect resulting in Rh(null) disease. Expression of rat kidney anion exchanger 1 in type A intercalated cells in metabolic acidosis and alkalosis. Acute acidosis and renal arteriovenous differences of glutamine in normal and adrenalectomized rats. Mechanism of altered renal glutaminase gene expression in response to chronic acidosis. Aldosterone requires vasopressin V1a receptors on intercalated cells to mediate acid-base homeostasis. Transport of citrate across renal brush border membrane: effects of dietary acid and alkali loading. Citrate uptake by basolateral and luminal membrane vesicles from rabbit kidney cortex. Regulation of thick ascending limb ion transporter abundance in response to altered acid/base intake. Basolateral expression of the ammonia transporter family member, Rh C glycoprotein, in the mouse kidney. Effect of reduced renal mass on renal ammonia transporter family, Rh C glycoprotein and Rh B glycoprotein, expression. Intercalated cell subtypes in connecting tubule and cortical collecting duct of rat and mouse. Aquaporin 2-labeled cells differentiate to intercalated cells in response to potassium depletion. Ammonia and bicarbonate transport by rat cortical collecting ducts perfused in vitro.

Order 20 gm betnovate with amex. PREGNANT MORNING ROUTINE.

The firing of pacemaker cells in the sinoatrial node determines heart rate skin care chanel order betnovate once a day, and several homeostatic mechanisms modulate cardiac pumping efficiency acne jokes generic betnovate 20 gm without a prescription. Superimposed on these intrinsic control processes to the heart and blood vessels are extrinsic factors that affect total cardiovascular function skin care during pregnancy betnovate 20 gm sale. These include the metabolic status of the tissues in which blood vessels are embedded and locally produced skin care giant crossword order 20 gm betnovate with amex, and blood-borne vasoactive chemicals (autocrine/paracrine/endocrine regulators) skin care products reviews by dermatologists purchase betnovate 20 gm fast delivery. It is essential to remember that arterial blood pressure is the product of cardiac output and total peripheral resistance. Blood flows through the vascular system, with cardiac output determined by the rate and efficiency of the pumping of the heart. Vascular resistance increases as the viscosity of the blood and the tone and length of blood vessels increases, particularly in precapillary arterioles, which represent the major structural determinant of vascular resistance. Thus understanding the physiological factors that regulate these three components (heart rate, stroke volume, and total peripheral resistance) will enable an individual to predict the activity of any given agent on cardiovascular function as it relates to blood pressure. The system is the primary mechanism by which oxygenated blood is delivered to tissues and exchanged for deoxygenated blood to maintain tissue/organ function. Much of this exchange occurs at the level of the capillaries and arterioles, where surface contact between the blood cells carrying oxygen and the tissues is greatest. The deoxygenated blood is returned to the heart and filtered through the lungs to replenish the oxygen carried in blood cells. While the system is relatively simple in design, it is essential to the normal physiology and is exquisitely controlled by the autonomic nervous system and several endogenous and/or innate regulatory processes. One such activity is represented by the baroreflex system, which monitors blood pressure on a beat-to-beat time frame to appropriately maintain homeostasis. The cardiovascular function is maintained to ensure adequate supply of nutrients and oxygen to generate the energy needed under normal conditions, as well as under situations of stress where greater energy is required. Because of its importance to normal physiology, abnormal functioning of the cardiovascular system can have enormous impact on the human body. Therefore understanding the operation of this system in normal physiology as well as in pathology is pivotal for our understanding of the mechanisms of action of current therapeutics as well as the identification of novel targets for developing therapeutic agents to manage cardiovascular disease. Much of the focus has been on the sympathetic nervous system and the renin-angiotensin-aldosterone system, due to the high visibility and importance that these systems play in modulating the cardiovascular system in health and disease. It is important to note that the sympathetic and parasympathetic innervations of cardiovascular end organs are tonically active, which means that activity can be modulated by either increasing or decreasing the firing rate of these nerves. Overall cardiac performance is influenced by both parasympathetic and sympathetic actions at different sites within the heart. Heart rate is decreased by parasympathetic activity and increased by sympathetic activity at the sinoatrial node, but the parasympathetic effect is usually dominant. The interaction between the parasympathetic and sympathetic innervation of the heart determines the heart rate measured at any particular time, as well as the heart rate variability. The latter is recognized as an important determinant of heart physiology, and its suppression is a predictor of myocardial pathology and mortality. Increased sympathetic activity reduces vascular caliber by contracting vascular smooth muscle. Although there are parasympathetic influences on a few vascular beds, their contribution to overall vascular resistance is insignificant. Constriction of veins in response to sympathetic activity reduces venous capacitance, thereby increasing venous return to the heart, which augments right atrial and ventricular filling; under healthy conditions, these cardiovascular responses increase cardiac output. However, it must also be remembered that sympathetically mediated constriction of arterioles can reduce cardiac output by increasing the vascular resistance (afterload) against which the heart must pump blood. Conversely, a reduction of sympathetic activity reduces blood pressure by diminishing the sympathetic stimulus and reduces the workload of the heart (O2 consumption). The preganglionic neurons of the sympathetic nervous system are located in the intermediolateral columns of the thoracolumbar region of the spinal cord. Antecedent to these final output neurons, much of the integration of neural signals contributing to autonomic regulation of cardiovascular function occurs at other sites in the brainstem, most notably the rostral ventrolateral medulla. Parasympathetic preganglionic neurons that project to the heart via the vagus nerves have low levels of spontaneous firing, and their discharge rate is driven mostly by inputs from various afferents, particularly arterial baroreceptors. Inputs to spinal sympathetic preganglionic neurons originate in the brainstem, pons, and hypothalamus and are mostly excitatory, primarily by activating neurons located in the rostral ventrolateral medulla, which is an important site in the central regulation of cardiovascular function and for many centrally active agents used to treat hypertension. Under physiological and pathophysiological conditions, the activity of autonomic nerves is regulated by neural signals arising from the periphery. Activation of visceral sensory nerves projecting to the brain via the vagus afferent nerves generally reduces sympathetic activity and increases parasympathetic activity. These afferents include stretch receptors located in the cardiovascular system, which provide information about arterial pressure (arterial baroreceptors) and cardiac filling (cardiac stretch receptors), as well as stretch receptors and chemosensory receptors in the lungs, which provide information about respiratory mechanics and lung irritants, respectively. Afferents with chemosensory terminals located in the carotid body encode blood gas O2 concentration, send projections to the brain via the glossopharyngeal nerve, and when activated by hypoxia, hypercapnia, or acidic pH, increase efferent sympathetic nerve activity. All of these afferents make their first central synapse within the nucleus of the tractus solitarius located in the dorsomedial brainstem. Aortic afferents (originating in the aortic arch) and sinus nerve afferents (originating in the carotid sinus) produce sympathoinhibition via activation of the caudal portion of the solitary tract nucleus, whereas glossopharyngeal afferents that produce sympathoexcitation project to more medial/rostral aspects of this nucleus. Other visceral mechanosensitive and chemosensitive nerve terminals are located throughout the body. Other sensory afferents do not travel with the sympathetic nerves and instead associate with various sensory-motor nerve trunks (somatic afferents) before synapsing in the spinal dorsal horns. All of these afferents typically encode noxious or painful chemical or mechanical stimuli, such as those associated with cardiac or visceral ischemia, visceral organ distention, or injury, and detect the metabolic products produced by exercising skeletal muscle. In addition to neural signals from the periphery, the brain also detects chemical signals (including drugs such as digitalis) that circulate in the blood. Activation of circumventricular organ neurons produces integrated autonomic, endocrine, and behavioral responses that can regulate a variety of physiological components, including salt and H2O balance and nutrient homeostasis, as well as cardiovascular function. The most important of the circumventricular organs for central autonomic control are the area postrema, subfornical organ, and organum vasculosum of the lamina terminalis. The principal role of this reflex is to ensure adequate organ perfusion, particularly to the brain, heart, and kidney, and to promote return of blood to the heart to counterbalance conditions that lower arterial blood pressure. Such conditions might include gravitational pooling of blood when assuming an upright posture and instances where blood volume is lost, such as during severe dehydration or hemorrhage. The baroreceptor reflex is also activated when drugs are used to lower blood pressure in hypertensive individuals, and this reflex may profoundly affect both the therapeutic outcomes and potential cardiac side effects caused by antihypertensive drug therapy. Sensory nerve endings embedded in the wall of the carotid sinus and aortic arch (baroreceptors) are activated by wall stretch that occurs when arterial pressure increases or decreases from a recognized set point. An increase in blood pressure triggers within a few seconds a simultaneous increase in vagal (parasympathetic) and a reduction in sympathetic activity. Parasympathetic activation slows the heart rate, and sympathetic inhibition results in passive vasodilation, thus tending to return arterial pressure toward normal. Conversely, a decrease in arterial pressure is rapidly countered by increased sympathetic and decreased parasympathetic activity. The baroreceptor reflex is important primarily in the short-term control of blood pressure. This change occurs to varying degrees with normal aging and in patients with heart failure or hypertension and is manifest by the failure of the baroreceptor reflex to respond when blood pressure is elevated for a prolonged period of time, referred to as baroreflex adaptation. The influence of baroreceptors on sympathetic nerve activity can vary greatly in different vascular beds. Some beds, such as the cutaneous vasculature, are largely independent of arterial baroreceptor influence and contribute little to total peripheral vascular resistance. In contrast, the baroreceptor reflex predominates in controlling sympathetic regulation of vascular diameter in many organs that receive a significant fraction of the cardiac output, such as skeletal muscle and the kidneys. For this reason, baroreflex regulation of sympathetic vasoconstriction plays an important role in determining total peripheral resistance. In fact, except under some special circumstances (exercise, sleep, and certain behavioral states), baroreceptors are able to override all other inputs affecting autonomic regulation of arterial blood pressure. This may reflect the importance of maintaining a stable systemic blood pressure to ensure adequate organ perfusion under diverse environmental conditions. Such drug-induced impairment compromises baroreceptor responsiveness and can result in orthostatic hypotension when the individual assumes the upright from the sitting position. On the other hand, some antihypertensive medications improve baroreceptor reflex function. Increased sympathetic effects can be produced by increased neural firing rate, increased catecholamine concentrations at the neuroeffector junction, and alterations at postjunctional receptors and signal transduction pathways. Although there is support for each of these mechanisms, the first two are most important, and drugs that inhibit sympathetic activity centrally and/or peripherally are useful for treating hypertension. Activation of prejunctional receptors modulates the probability that individual vesicles will discharge their contents by exocytosis congruent with depolarization; it does not affect the amount of transmitter released by individual vesicles. In contrast, activation of inhibitory heteroreceptors, such as occurs with adenosine, reduces the probability of vesicular exocytosis and transmitter release. In addition to prejunctional regulation of release, the concentration of neurotransmitter at neuroeffector junctions can be influenced by alterations in transmitter synthesis, storage within the nerve terminal, and removal from the neuroeffector junction by diffusion, metabolism, and reuptake. It must be remembered that the level of sympathetic activity, and ultimately blood pressure, is also modulated by central mechanisms. Some of the factors proposed to play a causative role in hypertension as a consequence of increasing sympathetic activity are listed in Box 36. These central and peripheral factors constitute well-characterized molecular targets for therapeutically prescribed antihypertensive medications. The left varicosity illustrates autoinhibition of neurotransmitter release, including possible "lateral" inhibition. The right varicosity illustrates prejunctional regulation of transmitter release by tissue and blood-borne chemicals. Postjunctional receptors are shown as yellow circles with the type of receptor noted,; prejunctional inhibitory autoreceptors are shown as squares,; prejunctional heteroreceptors are shown as dark triangles. Sympathetic activity to which of the following vascular beds is influenced the least by arterial baroreflexes Peripheral information from the lungs and heart are transmitted via sensory afferents to which nucleus in the brain Which of the following statements is correct with regard to autonomic control of blood vessels Although a small number (<10%) of people have hypertension traceable to specific causes such as renal disease or endocrine tumors, which are designated as secondary hypertension, the most common form of hypertension, which is present in over 90% of patients, has no readily identifiable cause and is termed essential or primary hypertension. Unless its onset is rapid and severe, hypertension does not produce noticeable symptoms. The purpose of treating hypertension is to circumvent end-organ injury and to prevent or reduce the severity of diseases such as atherosclerosis, coronary artery disease, aortic aneurysm, congestive heart failure, stroke, diabetes, and renal and retinal disease. Therapy of hypertension involves both pharmacological and nonpharmacological interventions. The therapeutic goal is to reduce blood pressure to below 150/90 mm Hg in patients 60 years of age or older and below 140/90 mm Hg in patients between the ages of 18­59 or 60 years of age or older with other underlying conditions such as diabetes, chronic kidney disease, or both. Adoption of healthy lifestyles may lower blood pressure as much as some drugs and may also prevent the onset or progression of hypertension, although patients differ in their sensitivity to these lifestyle changes. For example, maintenance of normal body weight and increased physical activity lowers blood pressure in most sedentary and overweight hypertensive individuals, whereas Na+ restriction lowers blood pressure mainly in hypertensive people categorized as "salt sensitive. While the lack of compliance by most people is a principal limitation of therapeutic lifestyle modification, lifestyle changes remain an important aspect of the management plan and should be recommended even when pharmacological therapy is initiated. Because drug therapy for hypertension must usually be continued for the lifetime of the patient, it is important to implement nonpharmacological interventions to enhance therapeutic outcome. Systemic blood pressure is regulated redundantly by several physiological control systems to ensure optimal tissue perfusion throughout the body (Chapter 36). Therefore it should not be surprising that agents employed in the therapeutic management of hypertension influence molecular targets in these systems. Although the goal of antihypertensive therapy is to reduce end-organ damage associated with chronically elevated blood pressure, the effects of therapy on other cardiovascular risk factors must also be considered. If an antihypertensive drug effectively lowers blood pressure but increases the influence of other risk factors for cardiovascular disease, the benefit of therapy may be reduced. In some studies, thiazide diuretics did not decrease the incidence of coronary artery disease, despite their ability to significantly reduce blood pressure. The number of medications available to treat hypertension has dramatically increased during the past three decades to over 50 medications designed for novel targets involved in the normal regulation of blood pressure. We have gained a more thorough understanding of the management of normal blood pressure, which has resulted in the identification of new targets and the development of new agents in those classes with improved therapeutic profiles. Despite these new agents, hypertension is not adequately managed in over 30% of patients, who are compliant with prescribed therapeutics, suggesting that new agents and/or modification to the standard strategies to manage hypertension are still needed. However, some of the historical compounds that reduce sympathetic tone overall still have important positions in the management scheme, particularly related to specific circumstances of hypertension. Even within the "standards," new molecular targets are being identified and used to develop new agents with more selective activities. It is significant to note that while new agents have been developed that target interruption of the sympathetic nervous system activity, the current standard of care still relies on the use of diuretics as one of the initial therapeutic entities. This is particularly important when the adopted therapeutic lifestyle changes are not sufficiently successful. While sympatholytic agents have an important place in the therapeutic strategies for treating hypertension, there remains great potential for future development of safer and more effective agents and strategies to manage this rapidly increasing disorder in the United States and worldwide. Overview of Hypertension Management Key Words 2-adrenergic receptor agonists -methyldopa -receptor blocking agents -receptor blocking agents centrally acting sympatholytics clonidine imidazoline receptor agonists imidazoline receptors peripherally acting sympatholytics 299. Other risk factors that can be affected by antihypertensive drugs include alterations in plasma levels of glucose and uric acid. In particular, insulin resistance is now recognized to be prevalent in patients with hypertension. Elevated insulin along with insulin resistance is a risk factor for coronary artery disease. Because of wide interpatient variability for risk factors and disease, therapeutic generalizations are difficult, and antihypertensive drug therapy must be tailored to each patient. These drugs have proven to be of clinical benefit, either alone or in combination, for several indications. The choice of therapy for a patient with essential hypertension depends on the initial blood pressure of the individual, as well as age, race, sex, family history of cardiovascular disease, and other risk factors, such as smoking, obesity, and sedentary lifestyle.

In many instances acne no more book betnovate 20 gm buy overnight delivery, systemic toxicities are so severe that the drug can only be administered topically skin care with honey 20 gm betnovate for sale. Because it is provided as a topical cream acne 5th grade 20 gm betnovate buy with visa, common side effects are burning acne light mask purchase 20 gm betnovate otc, swelling acne forum betnovate 20 gm order free shipping, or redness at the site of application. Allergic reactions such as difficulty breathing, facial swelling, and delirium are rare but serious adverse effects. Inhibitors of Viral Uncoating Common side effects observed after administration of amantadine and rimantadine include nausea, anorexia, insomnia, nervousness, and light-headedness. More severe central nervous system effects, including delirium, hallucinations, and seizures that have been attributed to increased dopaminergic neurotransmission, are more often observed with the use of amantadine. These effects are often seen in aged patients or patients with impaired renal function or seizure disorders. In addition, these effects may increase while using antihistamines, anticholinergic agents, hydrochlorothiazide, and trimethoprim-sulfamethoxazole. Approximately 10% of recipients exhibit hemolytic anemia and dyspnea in the initial weeks of therapy. Significant deterioration of pulmonary function has been reported in adults with chronic obstructive pulmonary disease and asthmatics receiving aerosol therapy. Ribavirin is contraindicated in pregnant women, as it is teratogenic and embryolethal in animal models. Patients exposed to ribavirin are advised not to conceive children for at least a 6-month period after exposure to the drug. Acyclovir is generally well tolerated, with 1% of patients experiencing nausea, diarrhea, and vomiting. Due to the basic nature of acyclovir (pH 9­11), phlebitis is the most common side effect, occurring in 15% of patients. Acyclovir undergoes renal excretion, and although uncommon, crystalline nephropathy and transient elevated creatinine concentrations can occur. Such effects can be prevented by sufficient hydration and avoidance of rapid infusion rate. Common side effects observed with sofosbuvir are fatigue, headache, nausea, and insomnia. Bradycardia has been reported in patients when sofosbuvir is coadministered with amiodarone and -adrenergic receptor blockers. Additionally, patients with a history of cardiac disease are at an increased risk of experiencing heart dysrhythmia with sofosbuvir. As a substrate of P-glycoprotein, sofosbuvir is not advised when taking other agents that modify P-glycoprotein activity, including rifampin. Because simeprevir is metabolized primarily via cytochrome P450s, caution is advised during coadministration with other agents metabolized by such enzymes, as higher plasma concentrations of simeprevir have been reported. In addition, simeprevir contains a sulfur and is contraindicated in patients with a sulfonamide allergy. Neuraminidase Inhibitors Possible side effects of oseltamivir include nausea, vomiting, and headache. Adverse effects observed with zanamivir are cough, bronchospasm, transient decrease in pulmonary function, and nasal and throat discomfort. Administration of zanamivir is not recommended in persons with an underlying airway disease, including asthma or chronic obstructive pulmonary diseases. Adverse effects observed in chronic therapy include neutropenia, alopecia, reversible hearing loss, thyroid dysfunction, mental confusion, and severe depression. In addition, caution is advised in patients with psychiatric pathologies, ischemic cardiac disease, thyroid disease, and epilepsy. Possible drug-drug interactions include theophylline, methadone, didanosine, and zidovudine, as concurrent use can worsen cytopenias. Immunoglobulins are well tolerated, with pain at the injection site and brief low-grade fever the most commonly reported side effects. Further, an antagonist of this receptor has been shown to protect animals from lethal infections. Thus further studies identifying new targets, such as this receptor, will undoubtedly lead to advances in drug development. Several of the clinical problems associated with the use of these agents are summarized in the Clinical Problems Box. Further, the discovery of emergent viruses, such as the Zika virus, necessitates new strategies for the continuous development of antiviral agents. Pathogenic viruses seem to be continuously emerging and reemerging, and major efforts are needed in many scientific arenas to combat unanticipated outbreaks. Although much progress has occurred in the past 20 years, more research is needed. Both professionals and their patients need to be aware of the early symptoms of viral infections and take all precautions not to spread disease. The rash has a dermatomal distribution from his spine around the left flank to the midline of the abdomen. A 25-year-old man was recently diagnosed with genital herpes and was prescribed acyclovir. Which of the following drugs is indicated for the treatment of either influenza A or influenza B Which drug combination would be the preferred treatment to eradicate the viral infection Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication. Formyl peptide receptor 2 plays a deleterious role during influenza A virus infections. This process is often accompanied by a flu-like illness, which will resolve on its own after a few weeks. The patient will then be asymptomatic for a variable period of time, usually 3­5 years. The gp120 is needed to attach to the host cell, and gp41 is critical for the cell fusion process. Of the nine virus genes, there are three-namely, gag, pol, and env-which contain the information needed to make structural proteins for new virus particles. Treatment of this virus continues to evolve with new drug combination regimens being developed continually. Because the optimal effectiveness of an antiviral agent depends on a competent host immune system that can help eliminate or effectively halt virus replication, immunosuppressed patients are prone to frequent and often severe infections that may recur when antiviral drugs are stopped. Treatment usually consists of three active agents with or without a boosting agent. Through a fusion process, the viral genome enters the cell, uncoats, and disassembles. Resistance occurs when mutations of gp41 are induced that alter conformation and folding. It is a thymidine analogue that is phosphorylated to mono-, di-, and triphosphate forms by cellular kinases in both infected and uninfected cells. It is an effective pharmacologic enhancer because it inhibits two key stages of metabolism. Ritonavir inhibits both of these proteins and consequently increases the maximum plasma concentration of a coadministered drug that interacts with these proteins. As rapidly increasing numbers of people, primarily gay men, but also intravenous drug users, began to get very sick and die, intensive research began. The first drug in this class, etravirine, 569 was approved in 2008, and the second drug in this class, rilpivirine, was approved in 2011. The first-single tablet regimen containing efavirenz, emtricitabine, and tenofovir was approved for use in 2006. These agents are very well tolerated and have a fairly high genetic barrier to resistance. To achieve higher concentrations of drug with fewer adverse effects, boosting agents are now commonly used. Entry Inhibitors Maraviroc is rapidly absorbed after oral administration and reaches peak plasma concentrations at 0. Elimination is thought to be mainly through enzymatic catabolism of the polypeptide to constituent amino acids. Importantly, the intracellular half-lives of the phosphorylated compounds are many hours. This can allow once- or twice-daily dosing for many of these agents, improving compliance and decreasing toxicity. Drug absorption is unique for each of the drugs in this class, and food or stomach pH can affect absorption for some of these agents. Tenofovir is not well absorbed by itself and is available as the alafenamide salt, which is a relatively new preparation that is less toxic than the traditional disoproxil salt. The alafenamide salt is much more stable in plasma than the disoproxil salt, enabling the achievement of higher intracellular levels of tenofovir at lower doses, leading to a >90% reduction of free tenofovir in plasma, greatly reducing potential toxicities. Efavirenz and rilpivirine possess the longest half-lives and can be given once daily. Efavirenz should be taken on an empty stomach, and rilpivirine should be taken with food to be most effective. Raltegravir and dolutegravir have no food restrictions, but elvitegravir/cobicistat should be taken with food. Raltegravir does not have the substantial drug-drug interaction potential of many other antiretrovirals because it is metabolized by glucuronidation, a low-affinity, high-capacity pathway. Because the absorption of these medications is usually improved with food, atazanavir and darunavir should both be taken with food. Inhibition of this enzyme can cause significant interactions with other medications. A positive test increases the chances of having a hypersensitivity reaction, so if the test is positive, alternative agents should be used. Tenofovir, as discussed, was formulated initially as the disoproxil salt, which causes proximal renal tubulopathy. Although this effect is generally subclinical, occasionally frank renal failure occurs, usually due to Fanconi syndrome. The recent reformulation of tenofovir as the alafenamide salt almost completely eliminates these toxicities by decreasing the amount of tenofovir present in plasma by over 90%. Tenofovir is also effective for the treatment of hepatitis B; thus in coinfected patients, this must always be taken into consideration. If tenofovir is discontinued, patients may have a severe flare-up of their hepatitis B, and treatment with another agent should be initiated promptly. One-third of patients taking nevirapine can develop significant rash, with life-threatening hypersensitivity reactions. Efavirenz use can be associated with severe depression and sleep disturbances, especially vivid dreams. A history of clinically significant depression is a relative contraindication for the use of efavirenz. It is very well tolerated, rendering it an excellent choice for patients who are very sensitive to medication adverse effects. Because maraviroc was never recommended for initial therapy, it is generally evaluated as an option for salvage therapy in treatment-experienced patients. The main side effects associated with enfuvirtide are reactions at the injection site, which can be quite severe and involve possible hypersensitivity reactions. This has significantly limited the utility of enfuvirtide, which is rarely used any more. Indinavir may precipitate in renal tubules and create clinically significant kidney stones, and thus adequate hydration is required for patients receiving this agent. However, the hyperbilirubinemia leads to jaundice or scleral icterus in only 5% of patients overall; less than 1% need to discontinue the drug due to this side effect. Several cases of cholelithiasis, with high levels of atazanavir found in the calculi, have been reported in patients who received atazanavir, and the use of atazanavir with or without ritonavir has also been associated with the development of nephrolithiasis. Raltegravir can cause elevations in amylase and in liver enzyme, but allergic reactions and drug interactions are infrequent. However, the efficacy of this strategy requires an ongoing commitment to adherence by patients. This is not an actual toxicity but needs to be distinguished from renal toxicity induced by tenofovir disoproxil, which can be difficult, as these agents are often given together in a single tablet. This tablet should not be given to patients with a creatinine clearance <70 mL/min and should be discontinued if the creatinine clearance drops below 50 mL/min. Discontinuation should be considered if the serum creatinine increases by more than 0. Immune-compromised patients are at risk for developing fungal infections, especially of the oral cavity, as well as malnutrition and anorexia, which predispose patients to malodor and coated tongue. It is important to determine the other agents being taken by these individuals to ensure that drug-drug interactions do not have a negative impact. Assessment of over-the-counter medications is also essential because many of these agents pose additional interactions. Fortunately, most patients who adhere to therapy can now achieve full virologic suppression with an undetectable viral load, which reduces the risk of transmission to a neglibigle amount. Caution should be exercised at all times to avoid inadvertent contact with bodily fluids, especially blood products. Which of the following most likely describes the reason for the failure of this second regimen He has also had diabetes mellitus since childhood and has renal insufficiency as a result, with a glomerular filtration rate of only 20 mL/min. Which of the following drugs does not need to be administered with a boosting agent This does not mean that all cancers are inherited, rather that neoplastic cells generally have an altered genetic content.

References

• Shah PJ, Dubey KP, Yadav JP: Predictive value of upper lip bite test and ratio of height to thyromental distance compared to other multivariate airway assessment tests for difficult laryngoscopy in apparently normal patients. J Anaesthesiol Clin Pharmacol 29:191, 2013.
• Solis Herruzo JA, Solis Munoz P, Munoz Yague T. The pathogenesis of primary biliary cirrhosis. Rev Esp Enferm Dig 2009;101(6):413-23.
• Martucci G, Landzberg M. Not just big kids: closing atrial septal defects in adults older than 60 years. Circ Cardiovasc Interv 2009;2:83-84.
• Shrier I. Is the placebo powerless? N Engl J Med. 2001;345(17): 1278; author reply 1278-1279.
• Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333: 1588-93.
• Rosell A, Monso? E, Soler N, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005; 165: 891-897.